Akorn long-term fundamentals remain unchanged, says Leerink Leerink says Akron's long-term fundamentals remain unchanged following the company's FY13 guidance call. The firm thinks management met expectations on the top line, provided a reasonable explanation on margins and slightly disappointed on manufacturing capacity expansion. Leerink raised its price target for Akorn shares to $16 from $14-$15 and keeps an Outperform rating on the name.
Akorn initiated with Outperform, $50 target at William Blair William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.